Epidemiology and treatment approaches in management of invasive fungal infections
暂无分享,去创建一个
[1] Elie Azoulay,et al. Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study* , 2011, Critical care medicine.
[2] R. Rajendran,et al. Azole Resistance of Aspergillus fumigatus Biofilms Is Partly Associated with Efflux Pump Activity , 2011, Antimicrobial Agents and Chemotherapy.
[3] G. Egerer,et al. Posaconazole prophylaxis in patients with acute myelogenous leukaemia – results from an observational study , 2011, Mycoses.
[4] B. Ener,et al. Acute invasive fungal rhinosinusitis: Evaluation of 26 patients treated with endonasal or open surgical procedures , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.
[5] M. Arendrup. Epidemiology of invasive candidiasis , 2010, Current opinion in critical care.
[6] J. Garbino,et al. Emerging invasive zygomycosis in a tertiary care center: epidemiology and associated risk factors. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[7] J. Ito,et al. Approaches to the early treatment of invasive fungal infection , 2010, Leukemia & lymphoma.
[8] E. Anaissie,et al. Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] E. Anaissie,et al. Factors associated with mortality in transplant patients with invasive aspergillosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] Michael Boeckh,et al. Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] J. Fishman,et al. Infection in organ transplantation: risk factors and evolving patterns of infection. , 2010, Infectious disease clinics of North America.
[12] A. Zaas,et al. Breakthrough Invasive Candidiasis in Patients on Micafungin , 2010, Journal of Clinical Microbiology.
[13] Thomas J Walsh,et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] E. Anaissie,et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[15] S. Oyonarte,et al. TNFR1 mRNA Expression Level and TNFR1 Gene Polymorphisms are Predictive Markers for Susceptibility to Develop Invasive Pulmonary Aspergillosis , 2010, International journal of immunopathology and pharmacology.
[16] B. Rabinow,et al. Nanosuspension Formulation of Itraconazole Eliminates the Negative Inotropic Effect of SPORANOX® in Dogs , 2010, Journal of Medical Toxicology.
[17] M. Battegay,et al. Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation , 2010, Bone Marrow Transplantation.
[18] C. Hennequin,et al. Acquisition of Flucytosine, Azole, and Caspofungin Resistance in Candida glabrata Bloodstream Isolates Serially Obtained from a Hematopoietic Stem Cell Transplant Recipient , 2009, Antimicrobial Agents and Chemotherapy.
[19] Jordi Rello,et al. International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.
[20] Hermann Einsele,et al. Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective , 2009, Biology of Blood and Marrow Transplantation.
[21] F. Aversa,et al. Polymorphisms in Toll-like receptor genes and susceptibility to infections in allogeneic stem cell transplantation. , 2009, Experimental hematology.
[22] J. Baddley,et al. Patterns of Susceptibility of Aspergillus Isolates Recovered from Patients Enrolled in the Transplant-Associated Infection Surveillance Network , 2009, Journal of Clinical Microbiology.
[23] M. Nucci,et al. Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Ito,et al. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] D. Denning,et al. Frequency and Evolution of Azole Resistance in Aspergillus fumigatus Associated with Treatment Failure , 2009, Emerging infectious diseases.
[26] E. Anaissie,et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] B. Spellberg,et al. Recent advances in the management of mucormycosis: from bench to bedside. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] L. Wheat. Approach to the diagnosis of invasive aspergillosis and candidiasis. , 2009, Clinics in chest medicine.
[29] T. Patterson,et al. Overview of antifungal agents. , 2009, Clinics in chest medicine.
[30] Ronald N. Jones,et al. Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007) , 2009, Journal of Clinical Microbiology.
[31] J. Sobel,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] E. Anaissie,et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[33] C. Lass‐Flörl,et al. In Vitro Activity of Isavuconazole against Aspergillus Species and Zygomycetes According to the Methodology of the European Committee on Antimicrobial Susceptibility Testing , 2009, Antimicrobial Agents and Chemotherapy.
[34] P. Warn. Efficacy of FG3409 a New Antifungal Agent, in Reducing Tissue Burden in Murine Models of Disseminated Aspergillosis , 2008 .
[35] L. Zhao,et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. , 2008, The New England journal of medicine.
[36] A. Hidrón,et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 , 2008, Infection Control & Hospital Epidemiology.
[37] L. Romani. Cell mediated immunity to fungi: a reassessment. , 2008, Medical mycology.
[38] D. Kontoyiannis,et al. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] C. Lass‐Flörl,et al. Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing , 2008, Antimicrobial Agents and Chemotherapy.
[40] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[41] J. Latgé,et al. Enumeration of functionally active anti-Aspergillus T-cells in human peripheral blood. , 2008, Journal of immunological methods.
[42] A. Espinel-Ingroff. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. , 2008, Revista iberoamericana de micologia.
[43] Raoul Herbrecht,et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] A. Cassone,et al. Fungal vaccines: real progress from real challenges. , 2008, The Lancet. Infectious diseases.
[45] Thierry Buclin,et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[46] S. de Botton,et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies , 2007, Cancer.
[47] G. Papanicolaou,et al. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[48] G. Sauvageau,et al. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[49] R. Betts,et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[50] L. Gordon,et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole , 2007, Bone Marrow Transplantation.
[51] S. Husain,et al. Fungal infections in solid organ transplantation. , 2007, Medical mycology.
[52] G. Fadda,et al. Biofilm Production by Candida Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia , 2007, Journal of Clinical Microbiology.
[53] J. Mehta,et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy , 2007, Bone Marrow Transplantation.
[54] K. Theunissen,et al. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders , 2007, Mycoses.
[55] J. Peter,et al. Concentration-Dependent Synergy and Antagonism within a Triple Antifungal Drug Combination against Aspergillus Species: Analysis by a New Response Surface Model , 2007, Antimicrobial Agents and Chemotherapy.
[56] W. Melchers,et al. A New Aspergillus fumigatus Resistance Mechanism Conferring In Vitro Cross-Resistance to Azole Antifungals Involves a Combination of cyp51A Alterations , 2007, Antimicrobial Agents and Chemotherapy.
[57] J. Lipton,et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.
[58] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[59] J. Demchok,et al. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. , 2006, The Journal of antimicrobial chemotherapy.
[60] B. Spellberg,et al. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. , 2006, The Journal of antimicrobial chemotherapy.
[61] D. Andes,et al. Pharmacology of Systemic Antifungal Agents , 2006 .
[62] D. Denning,et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis , 2006, Journal of Infection.
[63] D. Perlin,et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. , 2006, The Journal of antimicrobial chemotherapy.
[64] D. Kontoyiannis,et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[65] S. Holland,et al. Immunotherapy for fungal infections. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[66] R. Betts,et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients , 2006, Cancer.
[67] A. Tosti,et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. , 2005, Blood.
[68] D. Kim,et al. Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation , 2005, Bone Marrow Transplantation.
[69] E. C. Burton,et al. Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature. , 2005, MedGenMed : Medscape general medicine.
[70] B. Alexander,et al. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[71] W. Leisenring,et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[72] J. Mehta,et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients , 2005, Bone Marrow Transplantation.
[73] M. J. Buitrago,et al. Combined Activity In Vitro of Caspofungin, Amphotericin B, and Azole Agents against Itraconazole-Resistant Clinical Isolates of Aspergillus fumigatus , 2005, Antimicrobial Agents and Chemotherapy.
[74] D. Denning,et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[75] J. Lipton,et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[76] E. Manavathu,et al. Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[77] J. Perfect,et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[78] G. Byrnes,et al. Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation , 2004, Bone Marrow Transplantation.
[79] C. Montagnoli,et al. Dendritic cell-based vaccination against opportunistic fungi. , 2004, Vaccine.
[80] W. Leisenring,et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. , 2004, Blood.
[81] H. Kantarjian,et al. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy , 2004, Cancer.
[82] D. Maloney,et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation , 2004, Bone Marrow Transplantation.
[83] M. Pfaller,et al. Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi , 2003, Journal of Clinical Microbiology.
[84] J. Sobel,et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[85] Nina Singh,et al. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. , 2003, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[86] J. Perfect,et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.
[87] V. Kurup,et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. , 2002, Microbes and infection.
[88] E. Anaissie,et al. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[89] J. Ito,et al. Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. , 2002, The Journal of infectious diseases.
[90] Richard Sylvester,et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. , 2002, The New England journal of medicine.
[91] Lawrence Corey,et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[92] D. Kontoyiannis,et al. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients , 2002, Transplant infectious disease : an official journal of the Transplantation Society.
[93] G. Mejicano,et al. Vertebral osteomyelitis due to Candida species: case report and literature review. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[94] L. Saiman,et al. Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[95] M. Boeckh,et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.
[96] V. Kurup,et al. T Cell Vaccination in Mice with Invasive Pulmonary Aspergillosis1 , 2000, The Journal of Immunology.
[97] L. Mele,et al. Retrospective study of candidemia in patients with hematological malignancies. Clinical features, risk factors and outcome of 76 episodes , 1999, European journal of haematology.
[98] B. Lebeau,et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[99] D. Armstrong,et al. Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study. , 1999, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[100] A. Favero,et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[101] E. Manavathu,et al. Organism-Dependent Fungicidal Activities of Azoles , 1998, Antimicrobial Agents and Chemotherapy.
[102] B. Guglielmo,et al. Lipid formulations of amphotericin B: clinical efficacy and toxicities. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[103] J. Graybill,et al. Therapeutic drug monitoring of systemic antifungal therapy. , 1997, The Journal of antimicrobial chemotherapy.
[104] R. Semelka,et al. Hepatosplenic fungal disease: diagnostic accuracy and spectrum of appearances on MR imaging. , 1997, AJR. American journal of roentgenology.
[105] W. Leisenring,et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. , 1997, The Journal of infectious diseases.
[106] E. Jantunen,et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients , 1997, Bone Marrow Transplantation.
[107] R. Rabinovici,et al. Candida pericarditis: clinical profile and treatment. , 1997, The Annals of thoracic surgery.
[108] A. Groll,et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. , 1996, The Journal of infection.
[109] M. Levenstein,et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation--a prospective, randomized, double-blind study. , 1995, The Journal of infectious diseases.
[110] N. Müller,et al. Invasive aspergillosis of the airways: radiographic, CT, and pathologic findings. , 1994, Radiology.
[111] D. Denning,et al. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. , 1994, The Journal of antimicrobial chemotherapy.
[112] A. Schaffner,et al. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism , 1993, Mycoses.
[113] Y. Schneider,et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. , 1993, The Journal of clinical investigation.
[114] R. Semelka,et al. Detection of acute and treated lesions of hepatosplenic candidiasis: Conparison of dynamic contrast‐enhanced CT and MR Imaging , 1992, Journal of magnetic resonance imaging : JMRI.
[115] M. Okudaira,et al. Fungal infections in cancer patients: An international autopsy survey , 1992, European Journal of Clinical Microbiology and Infectious Diseases.
[116] E. Anaissie,et al. Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy. , 1991, The American journal of medicine.
[117] B. Hertenstein,et al. Infectious complications after allogeneic bone marrow transplantation with and without T-cell depletion of donor marrow , 1989, Infection.
[118] D. Maki,et al. Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Increased susceptibility to fungal infections. , 1986, Annals of internal medicine.
[119] E. Fishman,et al. Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis. , 1985, Radiology.
[120] Daniel B Hier,et al. Fungal infections of the central nervous system , 1985, Neurology.
[121] J. Miller,et al. Cutaneous lesions in disseminated candidiasis mimicking ecthyma gangrenosum. , 1981, The American journal of medicine.
[122] S. Rakower,et al. The risk of positive cultures for Candida in the critically ill patient , 1978, Critical care medicine.
[123] E. Sickles,et al. Clinical presentation of infection in granulocytopenic patients. , 1975, Archives of internal medicine.
[124] Bodey Gp. Infectious complications of acute leukemia. , 1966 .
[125] H. Kaufman. OCULAR INFLAMMATORY DISEASE. , 1964, The New England journal of medicine.
[126] P. Hunter,et al. Epidemiology of oral yeast colonization and infection in patients with hematological malignancies, head neck and solid tumors. , 2011, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.
[127] L. Pagano,et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. , 2011, Journal of Antimicrobial Chemotherapy.
[128] K. Sepkowitz,et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[129] K. Engels,et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. , 2010, The Journal of infection.
[130] Samuel A. Lee,et al. Loss of in vitro resistance in Candida glabrata following discontinuation of fluconazole prophylaxis in a hematopoietic stem cell transplantation patient. , 2010, Medical mycology.
[131] Jay Steingrub,et al. International study of the prevalence and outcomes of infection in intensive care units , 2009 .
[132] B. Thiers. Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia , 2008 .
[133] J. Perfect,et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[134] J. Mardiak,et al. Invasive mold infections in cancer patients: 5 years' experience withAspergillus, Mucor, Fusarium andAcremonium infections , 2005, Supportive Care in Cancer.
[135] J. Meis,et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. , 2003, The Journal of antimicrobial chemotherapy.
[136] B. Kleinschmidt-DeMasters. Central nervous system aspergillosis: a 20-year retrospective series. , 2002, Human pathology.
[137] L. Mele,et al. Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. , 2002, Haematologica.
[138] M. Ghannoum,et al. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. , 1999, Antimicrobial agents and chemotherapy.
[139] J. Raemaekers,et al. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. , 1993, Leukemia & lymphoma.
[140] D. Dunn,et al. Analysis of infectious complications occurring after solid-organ transplantation. , 1992, Archives of surgery.
[141] K. White,et al. Clinical epidemiology. , 1983, International journal of epidemiology.
[142] G. Bodey. Infectious complications of acute leukemia. , 1966, Medical times.
[143] R. Tuckuviene,et al. submit your manuscript | www.dovepress.com , 2022 .